Presentation is loading. Please wait.

Presentation is loading. Please wait.

David Lim, Julie Hepworth, Evan Siegel, Mieke van Driel, & Lisa Nissen

Published byEunice Briana Bryant Modified over 6 years ago

Similar presentations

Presentation on theme: "David Lim, Julie Hepworth, Evan Siegel, Mieke van Driel, & Lisa Nissen"— Presentation transcript:

1 David Lim, Julie Hepworth, Evan Siegel, Mieke van Driel, & Lisa Nissen
Interferon-free therapy for hepatitis C, how prepared is Australia for biosimilars? David Lim, Julie Hepworth, Evan Siegel, Mieke van Driel, & Lisa Nissen (C)

2 Standard treatment for Hepatitis C
Peginterferon alfa-2A PegasysTM; Roche 5 repeats Dispensed price $2, $2,747.09 Maximum safety net $36.10 Peginterferon alfa-2A with ribavirin Pegasys RBVTM; Roche Dispensed price $3, $3,452.99 PegatronTM; Merck Sharp & Dohme Dispensed price $2, $4,411.11 Triple combination therapy with either Boceprevir (VictrelisTM; Merck Sharp & Dohme) 200mg capsule, 336 capsules, 10 repeats Dispensed price $3,920.00 Telaprevir (IncivoTM; Jassen-Cilag) 375mg tablet, 42 tablets, 6 repeats Dispensed price $14,912.37

3 Schering-Plough/ Merck Tibotec Vertex C NS5A inhibitors AstraZeneca
Protease inhibitors AbbVie Achillion Boehringer Ingelheim Bristol-Myers Squibb Conatus Genetech/ Roche Gilead Sciences Merck Sharp & Dohme Schering-Plough/ Merck Tibotec Vertex C NS5A inhibitors AstraZeneca Can-Fite Chugai/ Roche/ Genetech Presidio Polymerase inhibitors Anadys Idenix Inhibitex Medivir/ Tibotec Pfizer Pharmasset Roche/ Genetech Vertez RNA interference Santaris Pharmaceuticals Cyclophilin inhibitors Novartis Synexis ABT-267 Clemizole Eiger BioPharmaceuticals Nitazoxanide Romark Laboratories Silibinin Buckwang Phgarmaceuticals Medical University of Vienna Mouunt Sinai School of Medicine National Centre for Complementary and Alternative Medicine University of Maryland University of North Carolina-Chapel Hill Novel interferons Amarillo Biosciences/ CytoPharm Biolex Therapeutics Bristol-Myers Squibb/ ZymoGenetics Digna Biotech Flamel Technologies HanAll BioPharma Vaccines Globeimmune Intercell AG Inovio/ Tripep Okairos Transgene Toll-like receptor stimulators Anadys Gilead Sciences Idera Pharmaceuticals Cytokines Cytheris Novelos Monoclonal antibodies Centocor Ortho Biotech Cure Tech Mass Biologics Peregrine Pharmaceuticals Photo: Microsoft, Clip Art

4 http://www. tevagenerics

5 National Prescribing Service, Evidence versus Hype workshop

6 http://ideas2market. wordpress

7

8 CC-BY Bruce Irving, FlyingSinger

9 © Dispensing Doctor Association, UK. Used with permission.

10

11 Nomenclature of biosimilars e.g. Epoetin in Australia
epoetin alfa (EprexTM; Janssen-Cilag) epoetin beta (NeoRecormonTM; Roche) epoetin lambda (NovicritTM; Novartis) darbepoetin alfa (AranespTM; Amgen) methoxy polyethylene glycol-epoetin beta (MirceraTM; Roche)

12 Biosimilar epoetin epoetin alfa (EprexTM; Janssen-Cilag)
EpogenTM; Amgen (US) ProcitTM; Johnson & Johnson (US) Epoetin alfa HexalTM; Hexal Biotechn Forschungs (Germany) AbseamedTM; Medice Arneimittell Putter (Germany) epoetin beta (NeoRecormonTM; Roche) epoetin lambda (NovicritTM; Novartis) BinocritTM; Sandoz-Azicrit/ Novartis (EPO-a in Europe) Grandicrit Epoetin delta (DynepoTM; Shire Pharmaceuticals) Epoetin omega (RepotinTM; Bioclones) Epoetin zeta RetacritTM; Hospira SilapoTM; Stada Arneimittel AG darbepoetin alfa (AranespTM; Amgen) methoxy polyethylene glycol-epoetin beta (MirceraTM; Roche)

13 Policy consideration

14

15 © Commonwealth of Australia, Department of Health and Ageing 2002, The National Strategy for Quality Use of Medicines. Used with permission.

16 CC-BY,NC,ND: www.flickr.com/photos/ionushi

Download ppt "David Lim, Julie Hepworth, Evan Siegel, Mieke van Driel, & Lisa Nissen"

Similar presentations

Introduction Charles B. Hicks, MD Professor of Medicine Associate Director, Duke AIDS Research and Treatment Center Duke University Medical Center Durham,

Introduction Charles B. Hicks, MD Professor of Medicine Associate Director, Duke AIDS Research and Treatment Center Duke University Medical Center Durham,
Preparing for Direct Acting Antivirals (DAAs) in PracticeNew Paradigms in the Management of HCV Sherilyn C. Brinkley, MSN, CRNP Nurse Practitioner/Program.

Preparing for Direct Acting Antivirals (DAAs) in PracticeNew Paradigms in the Management of HCV Sherilyn C. Brinkley, MSN, CRNP Nurse Practitioner/Program.
Rethinking Lower Blood Pressure Goals for Diabetic Patients with Coronary Artery Disease – Findings from the INternational VErapamil SR – Trandolapril.

Rethinking Lower Blood Pressure Goals for Diabetic Patients with Coronary Artery Disease – Findings from the INternational VErapamil SR – Trandolapril.
The golden standard or fools gold Selective data, impact on safety Clinical trials on trial HAI Europe Open Seminar 2008 Neues Stadthaus, Berlin, 21 November.

The golden standard or fools gold Selective data, impact on safety Clinical trials on trial HAI Europe Open Seminar 2008 Neues Stadthaus, Berlin, 21 November.
Collaboration in the Life Sciences November 2011.

Collaboration in the Life Sciences November 2011.
Is Australia ready for ? Is Australia ready for biosimilar ? David Lim, Julie Hepworth, Lisa Nissen CC-BY,NC Sarah Macmillan.

Is Australia ready for ? Is Australia ready for biosimilar ? David Lim, Julie Hepworth, Lisa Nissen CC-BY,NC Sarah Macmillan.
Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV.
Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.

Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.
Protease and Polymerase Inhibitors for the Treatment of Hepatitis C

Protease and Polymerase Inhibitors for the Treatment of Hepatitis C
BUY Recommendation: Gilead Sciences (GILD). Company Overview Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers,

BUY Recommendation: Gilead Sciences (GILD). Company Overview Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers,
PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.
Direct Acting Antivirals: What are they

Direct Acting Antivirals: What are they
Corporate presentation, [ ] 2011 NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE OR SOUTH AFRICA A specialty.

Corporate presentation, [ ] 2011 NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE OR SOUTH AFRICA A specialty.
2014. Diamond Members  Alexion  Bristol Myers Squibb  Cardinal Health  Eisai, Inc.  Foundation Medicine  Genomic Health  McKesson  MedImmune.

2014. Diamond Members  Alexion  Bristol Myers Squibb  Cardinal Health  Eisai, Inc.  Foundation Medicine  Genomic Health  McKesson  MedImmune.
Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical.

Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical.
Only infects humans and chimpanzees This is a virus that mainly affects the Liver – Asymptomatic Only lives for about 16 hours outside the human body.

Only infects humans and chimpanzees This is a virus that mainly affects the Liver – Asymptomatic Only lives for about 16 hours outside the human body.
How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,
A systematic review of hepatitis C clinical practice guidelines: Benefits, limitations and harms Lim, D., Siegel, E., Hepworth, J., Bain, T., and van Driel,

A systematic review of hepatitis C clinical practice guidelines: Benefits, limitations and harms Lim, D., Siegel, E., Hepworth, J., Bain, T., and van Driel,
U.S. Pharmacogenomics Markets Key Alliances and Pro-Active Networking Efforts Essential for Success Investors and established companies should begin scouting.

U.S. Pharmacogenomics Markets Key Alliances and Pro-Active Networking Efforts Essential for Success "Investors and established companies should begin scouting.

Similar presentations

Ads by Google